Scientific update

Measure interaction strength between target cell and TCR T-cell in HPV-related cancers with the z-Movi®

In a recent review article in Immunology, Fakhr et al. presented the z-Movi® Cell Avidity Analyzer as a solution to characterize T-cell populations by measuring the binding strength between immune and cancer cells using non-invasive acoustic force. Binding events between a T-cell and its target cell determine the initiation of immunological synapse formation and T-cell activation. Cell– cell interactions are, therefore, crucial to consider when trying to comprehend T-cell response processes.

The article reviews various immunotherapies for cancers caused by human papillomaviruses (HPV), with a focus on engineered TCR T-cells. Typically, the final step in an optimal workflow for the identification of tumor-specific TCR sequences and the construction of engineered TCR T-cells, requires the characterization of the engineered TCR T-cells for avidity and functionality.

“Engineered T-cells that meet the functional and structural avidity criteria and show efficient tumor eradication in vivo can then be considered as good candidates for clinical trials”

This article suggests that the z-Movi can identify and validate effective T-cells against HPV-related cancers. Researchers can use the z-Movi to increase the validity of their immunotherapy development research, and expedite their search in potent T-cell candidates.

Thanks to all the authors for acknowledging our instrument! Learn more about various immunotherapies against HPV-associated cancers in the full article titled “Recent developments in immunotherapy of cancers caused by human papillomaviruses” in Immunology : The journal of cells, molecules, systems and technologies.

No items found.

No items found.

No items found.

Related scientific updates

Learn as much as you can by reading up on our scientific updates.

View all
Text Link
Enhancing efficacy against clear cell renal cell carcinoma through format-tuning of bispecific T cell engagers

Enhancing efficacy against clear cell renal cell carcinoma through format-tuning of bispecific T cell engagers

Scientific update
January 29, 2025
01-01-20

Text Link
Study using CTFM Published in Nature Communications

Study using CTFM Published in Nature Communications

Scientific update
June 15, 2016
01-01-20

Text Link
AFS 2.0 Paper Published in Methods

AFS 2.0 Paper Published in Methods

Scientific update
June 5, 2016
01-01-20

Text Link
Paper Using LUMICKS Technology Published in Nature

Paper Using LUMICKS Technology Published in Nature

Scientific update
July 21, 2016
01-01-20

No items found.